Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Molnupiravir

An oral antiviral born at Emory University in Atlanta from research on Venezuelan equine encephalitis virus: it is a prodrug of a cytidine analogue, first approved in the United Kingdom in November 2021 for COVID-19. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?Its name was inspired by Mjölnir, the hammer of the Norse god Thor: the medicine 'strikes' the virus by making it accumulate so many mutations in its RNA that it can no longer survive.

MolnupiravirGo to the active ingredient →
MolnupiravirActive ingredientMolnupiravirCat. No. P-M160-001CAS 2492423-29-5

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.